Treatment for Lightening Menstruation (Heavy Menstrual Bleeding)
For most women with heavy menstrual bleeding, start with the levonorgestrel-releasing intrauterine device (LNG-IUD 20 μg/day), which reduces menstrual blood loss by 71-95% and is the most effective medical therapy available. 1
First-Line Medical Options
The treatment hierarchy depends on your contraceptive needs and medical history:
Most Effective: Levonorgestrel IUD
- The LNG-IUD (20 μg/day) is comparable in efficacy to endometrial ablation and is the only progestin IUD with proven effectiveness for heavy bleeding 1
- Works primarily at the endometrial level with minimal systemic absorption
- Provides dual benefit of contraception and bleeding reduction
- A lower-dose device (14 μg/day) is available but lacks specific evidence for heavy bleeding 1
Alternative Medical Therapies
Tranexamic acid:
- Reduces menstrual blood loss by approximately 53 mL per cycle compared to placebo 2
- Effective in reducing bleeding volume and transfusion needs 3
- Important contraindication: Avoid in women with cardiovascular disease (SCAD) due to thrombosis risk 1
- Standard dosing: 5-7 days of treatment 4
Combined hormonal contraceptives (CHCs):
- Significantly more effective than placebo for heavy bleeding 2
- Contraindicated in women with cardiovascular disease or SCAD 1
- Can be used as 10-20 days of treatment for acute bleeding 4
NSAIDs (mefenamic acid, naproxen):
- Reduce menstrual blood loss but less effective than tranexamic acid 2
- Use for 5-7 days during menstruation 4
- Avoid in women with cardiovascular disease due to MI risk 1
Oral progestogens:
- Cyclic oral progestin reduces bleeding by 87% 1
- Often results in irregular bleeding with reduction to light flow
- Can be used when estrogen-containing methods are contraindicated
Special Populations
Women on Antiplatelet Therapy (Post-SCAD)
This is a critical scenario where standard treatments are restricted:
- First reassess: Discontinue antiplatelet therapy if no longer indicated 1
- Preferred option: LNG-IUD (20 μg/day) - works locally with minimal systemic effects 1
- Avoid: NSAIDs, tranexamic acid, and combined hormonal contraceptives due to MI/thrombosis risk 1
- Alternative: Cyclic oral progestin (despite theoretical concerns) or consider endometrial ablation 1
Women on Anticoagulation
- Progestin-only methods are preferred 5
- GnRH agonists can be considered 5
- Tranexamic acid can be used with same indications as non-anticoagulated patients 3
Acute Heavy Bleeding Requiring Urgent Intervention
Defined as bleeding saturating a large pad/tampon hourly for ≥4 hours 1:
- Assess hemodynamic stability (orthostatic vitals) 6
- Test for pregnancy in all reproductive-age women 1, 6
- Medical management first-line:
- Reserve surgery for non-responders to medical therapy 6
When Medical Therapy Fails
Surgical options to consider:
- Second-generation endometrial ablation (thermal balloon, microwave, radiofrequency) - more effective long-term than oral medical treatment 1
- Hysterectomy for definitive management 7
Advantages of ablation:
- Effective bleeding control
- Reduces pregnancy risk
- Avoids need for ongoing hormonal therapy 1
Critical Pitfalls to Avoid
- Do not use NSAIDs or tranexamic acid in women with cardiovascular disease - both increase MI and thrombosis risk 1
- Do not use combined hormonal contraceptives in women with SCAD or cardiovascular disease - relatively contraindicated 1
- Always exclude pregnancy before initiating treatment in reproductive-age women 1, 6
- Check for anemia (including ferritin) and underlying bleeding disorders, especially in adolescents 6
- Monitor hemoglobin and provide iron supplementation during menstrual flow in women on anticoagulation 8
Monitoring Heavy Menstrual Bleeding
- Women should be taught to quantify bleeding (pad/tampon saturation) 8
- Periodic hemoglobin monitoring in premenopausal women on anticoagulation 8
- If bleeding persists despite treatment, investigate for underlying structural pathology 4
The evidence strongly supports the LNG-IUD as first-line therapy for most women, with treatment selection modified based on cardiovascular risk factors, anticoagulation status, and contraceptive needs.